Receptor selectivity

The answer to what is receptor selectivity: it is how strongly a compound prefers its intended receptor over other receptors at the same concentration. High selectivity narrows the biological splash zone. It can reduce certain side effects, but it does not make a compound stronger, perfectly specific, or automatically safe.

What does “selective peptide” mean?

The selective peptide meaning is preference, not exclusivity. A selective compound acts at one receptor more readily than others; a non-selective compound meaningfully activates several. In a selective vs non-selective agonist comparison, researchers look at binding affinity or concentration-response data across receptors—not which compound produces the biggest headline effect.

That distinction separates a receptor selectivity definition from potency. Potency asks how much compound produces an effect. Selectivity asks where those effects occur. Selectivity is also dose-dependent: raising concentration can recruit lower-affinity targets that barely responded at a lower concentration. “Selective” never means “hits only one receptor under every condition” (Berg and Clarke, 2018).

Why does receptor selectivity matter for side effects?

Receptor selectivity matters because activity at an unintended receptor can create off-target effects. A narrower target profile may leave fewer routes to unwanted effects. That is a side-effect story, not a strength story: a highly selective agonist can be weak, while a potent agonist can still be pharmacologically messy.

Not every side effect is off-target. A compound can activate its intended receptor in the wrong tissue, or trigger an unwanted pathway through that same receptor. Hunger from a ghrelin-receptor agonist, for example, may be on-target biology. Cortisol or prolactin changes can also be downstream hormone effects rather than proof that the compound bound their receptors directly.

Why is ipamorelin called selective?

Ipamorelin is called selective because the original preclinical study found growth-hormone release without the ACTH and cortisol rise seen with GHRP-2 and GHRP-6. That result came from rat cells, rats, and swine—not a human receptor-panel study—and described selective hormone output more directly than selective receptor binding (Raun et al., 1998).

Ipamorelin shows why asking what is receptor selectivity needs an evidence tier, not just a label.

Human evidence confirms that ipamorelin produces a growth-hormone pulse, but that study measured ipamorelin and growth hormone rather than cortisol, prolactin, appetite, or a broad off-target panel (Gobburu et al., 1999). So the careful claim is narrow: ipamorelin showed selective GH release preclinically. The wider human side-effect advantage remains less settled. See the growth-hormone peptide family for the surrounding class.